MARKET

ADMS

ADMS

Adamas Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.55
-0.06
-0.98%
After Hours: 5.55 0 0.00% 16:00 11/15 EST
OPEN
5.60
PREV CLOSE
5.60
HIGH
5.66
LOW
5.44
VOLUME
269.56K
TURNOVER
--
52 WEEK HIGH
12.57
52 WEEK LOW
3.350
MARKET CAP
154.47M
P/E (TTM)
-1.3757
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ADMS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ADMS News

  • Adamas Announces New Employment Inducement Grant
  • GlobeNewswire.11/08 21:01
  • The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut
  • Benzinga.11/08 13:16
  • The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut
  • Benzinga.11/08 13:14
  • Mixed shelf roundup - healthcare
  • seekingalpha.11/08 03:02

More

Industry

Biotechnology & Medical Research
+1.61%
Pharmaceuticals & Medical Research
+1.32%

Hot Stocks

Name
Price
%Change

About ADMS

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).
More

Webull offers Adamas Pharmaceuticals Inc (ADMS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.